Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event

  • Upcoming R&D sessions on oncology, Dupixent® (dupilumab), and nirsevimab
  • Initial session focused on brain-penetrant BTKi ‘168 Phase 2 data
  • Virtual R&D day event on June 23 to showcase Sanofi’s industry leading platforms, unique capabilities, and innovative medicines to fuel future growth


PARIS – May 18, 2020 – Sanofi announced today that it is hosting a series of interactive webcast events highlighting key priority pipeline programs that will conclude with the company’s virtual R&D day event on Tuesday, June 23. The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofi’s development strategy for its brain-penetrant BTKi’168 for multiple sclerosis in April. Upcoming sessions will discuss Sanofi’s oncology strategy, line extension plans for Dupixent® (dupilumab), and nirsevimab, the first time a monoclonal antibody potentially offers a population-based solution to prevent respiratory syncytial virus (RSV) for all infants.

Over the coming weeks, we look forward to sharing the tremendous progress we’ve made in advancing our priority molecules and building a sustainable R&D engine,” said John Reed, Global Head of Research and Development at Sanofi.  “With a great team, deep therapeutic area expertise and an expanding toolbox of therapeutic platforms, Sanofi is poised to discover the next generation of life-changing medicines.

Upcoming events

Oncology Strategy and ASCO R&D Investor Event
June 2, 2020 - 4:00 pm CET / 10 am ET (1.5 hours)

Dupixent R&D Investor Event
June 11, 2020 - 3:00 pm CET / 9:00 am ET (1.5 hours)

Nirsevimab R&D Investor Event
Date to follow - 3:00 pm CET / 9:00 am ET (1.5 hours)

Virtual R&D Day Event
June 23, 2020 - 3:00 pm CET / 9:00 am ET (2.5 hours)
Additional information about these upcoming events can be found at https://www.sanofi.com/en/investors

 

About Sanofi

 

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

 

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

 

Sanofi, Empowering Life

 



Media Relations Contact
Ashleigh Koss
Tel.: +1 908 205 2572
ashleigh.koss@sanofi.com


Investor Relations Contact
Felix Lauscher
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com

 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing  could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

 


Attachment